Literature DB >> 15735654

The mechanism underlying the contractile effect of a chemotactic peptide, formyl-Met-Leu-Phe on the guinea-pig Taenia coli.

Hiroshi Kawata1, Katsuya Hirano, Junji Nishimura, Chiharu Kubo, Hideo Kanaide.   

Abstract

1 The contractile mechanism of N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) was investigated in the guinea-pig Taenia coli, by simultaneously monitoring the changes in the cytosolic Ca(2+) concentration ([Ca(2+)](i)) and force. 2 fMLP induced a significant elevation of [Ca(2+)](i) and force at concentrations higher than 10 nM. The maximal response was obtained at a concentration of higher than 1 microM. 3 fMLP (10 microM) augmented the force development induced by a stepwise increment of the extracellular Ca(2+) concentration during 60 mM K(+) depolarization, while it had no effect on the [Ca(2+)](i) elevation, and thus produced a greater force for a given elevation of [Ca(2+)](i) than 60 mM K(+) depolarization. 4 The removal of extracellular Ca(2+) completely abolished the fMLP-induced contraction. The fMLP-induced [Ca(2+)](i) elevation was inhibited substantially but not completely by 10 microM diltiazem, partly by 10 microM SK&F 96365, and completely by their combination. 5 Y27632, a specific inhibitor of rho-kinase, had no significant effect on the fMLP-induced [Ca(2+)](i) elevation and force development. 6 Chenodeoxycholic acid, a formyl peptide receptor antagonist, specifically abolished the fMLP-induced contraction but not high K(+)- or carbachol-induced contractions. 7 A dual lipoxygenase/cyclooxygenase inhibitor, a 5-lipoxygenase inhibitor, a nonselective leukotriene receptor antagonist, and a selective type 1 cysteinyl-containing leukotriene receptor antagonist specifically reduced the fMLP-induced contraction. 8 We suggest that the low-affinity-type fMLP receptor and lipoxygenase metabolites of arachidonic acid are involved in the fMLP-induced contraction in the guinea-pig T. coli. This contraction mainly depends on the [Ca(2+)](i) elevation due to Ca(2+) influx and the enhancement of Ca(2+) sensitivity in the contractile apparatus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735654      PMCID: PMC1576144          DOI: 10.1038/sj.bjp.0706181

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  Expression of functional formyl peptide receptors by human astrocytoma cell lines.

Authors:  Y Le; J Hu; W Gong; W Shen; B Li; N M Dunlop; D O Halverson; D G Blair; J M Wang
Journal:  J Neuroimmunol       Date:  2000-11-01       Impact factor: 3.478

Review 2.  Receptors for chemotactic formyl peptides as pharmacological targets.

Authors:  Yingying Le; Yiming Yang; Youhong Cui; Hiroshi Yazawa; Wanghua Gong; Cunping Qiu; Ji Ming Wang
Journal:  Int Immunopharmacol       Date:  2002-01       Impact factor: 4.932

3.  The mechanism for the contraction induced by leukotriene C4 in guinea-pig taenia coli.

Authors:  S Ieiri; J Nishimura; K Hirano; S Suita; H Kanaide
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

Review 4.  Protein kinase network in the regulation of phosphorylation and dephosphorylation of smooth muscle myosin light chain.

Authors:  Katusya Hirano; Dmitry N Derkach; Mayumi Hirano; Junji Nishimura; Hideo Kanaide
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

5.  Characterization of two new members of the formyl peptide receptor gene family from 129S6 mice.

Authors:  Zhen-Guo Wang; Richard D Ye
Journal:  Gene       Date:  2002-10-16       Impact factor: 3.688

Review 6.  Cellular responses to FMLP challenging: a mini-review.

Authors:  M A Panaro; V Mitolo
Journal:  Immunopharmacol Immunotoxicol       Date:  1999-08       Impact factor: 2.730

7.  The ACh-induced contraction in rat aortas is mediated by the Cys Lt1 receptor via intracellular calcium mobilization in smooth muscle cells.

Authors:  Luca Mazzetti; Sergio Franchi-Micheli; Silvia Nistri; Silvia Quattrone; Ruggero Simone; Mario Ciuffi; Lucilla Zilletti; Paola Failli
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

Review 8.  Leukotriene receptors: classification, gene expression, and signal transduction.

Authors:  Takashi Izumi; Takehiko Yokomizo; Hideru Obinata; Hideaki Ogasawara; Takao Shimizu
Journal:  J Biochem       Date:  2002-07       Impact factor: 3.387

Review 9.  Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs.

Authors:  J Martel-Pelletier; D Lajeunesse; P Reboul; J-P Pelletier
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

Review 10.  Enzymes and receptors in the leukotriene cascade.

Authors:  J Z Haeggström; A Wetterholm
Journal:  Cell Mol Life Sci       Date:  2002-05       Impact factor: 9.261

View more
  1 in total

1.  Inhibition of 15-lipoxygenase (15-LOX) reverses hypoxia-induced down-regulation of potassium channels Kv1.5 and Kv2.1Inhibition of 15-lipoxygenase (15-LOX) reverses hypoxia-induced down-regulation of potassium channels Kv1.5 and Kv2.1.

Authors:  Wenjuan Liu; Di Wang; Kaibin Song; Li Chen; Yanmei Zhu; Peifang Liu; Yulan Zhu
Journal:  Int J Clin Exp Med       Date:  2014-11-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.